NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.co ...

NEW YORK, April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=145053&from=4 CLASS PERIOD: ...

文章核心观点 罗森律师事务所提醒在2023年3月17日至2024年11月4日期间购买Sana Biotechnology公司证券的投资者2025年5月20日为首席原告截止日期，投资者可通过风险代理安排获得赔偿 [1] 案件详情 - 被告在集体诉讼期间作出虚假或误导性陈述，未披露Sana资金不足、部分产品前景不佳、可能减少相关产品资金投入和裁员等情况，导致投资者受损 [4] 参与集体诉讼方式 - 可访问https://rosenlegal.com/submit - form/?case_id = 37267，或致电866 - 767 - 3653，或发邮件至case@rosenlegal.com了解相关信息 [2][5] 选择罗森律师事务所原因 - 该律所代表全球投资者，专注证券集体诉讼和股东派生诉讼，曾达成针对中国公司的最大证券集体诉讼和解，2017年证券集体诉讼和解数量排名第一，自2013年起每年排名前4，为投资者追回数亿美元，2019年为投资者获超4.38亿美元赔偿 [3]

文章核心观点 Faruqi & Faruqi律师事务所调查针对Sana Biotechnology的潜在索赔，提醒投资者5月20日2025年截止日期争取联邦证券集体诉讼首席原告角色，鼓励受损投资者联系讨论法律权利 [4][1] 律所信息 - Faruqi & Faruqi是领先的全国性证券律师事务所，在纽约、宾夕法尼亚、加利福尼亚和佐治亚设有办事处，自1995年成立以来为投资者追回数亿美元 [5] 诉讼指控 - 公司及其高管违反联邦证券法，做出虚假或误导性陈述，未披露公司资金不足、部分产品前景不佳、可能减少项目资金和裁员等情况，夸大财务能力 [6] 公司事件及股价反应 - 2023年10月10日盘后，公司宣布减少体内基因递送融合原平台近期支出，增加离体细胞疗法平台投入，推迟SG299新药研究申请，减少29%员工，2024年运营现金消耗低于2亿美元，11日股价下跌0.34美元/股，跌幅8.95%，收于3.46美元/股 [7][8] - 2024年11月4日盘后，公司宣布暂停肿瘤学SC291和SC379开发，增加1型糖尿病项目投资，延长现金储备至2026年，5日股价下跌0.37美元/股，跌幅9.84%，收于3.39美元/股 [9] 首席原告相关 - 法院指定的首席原告是在集体寻求的救济中财务利益最大、能代表集体成员的投资者，可选择争取该角色或不作为缺席成员，是否担任不影响赔偿分享 [10] 信息提供与咨询 - 鼓励了解Sana行为信息的人联系律所，可访问网站或致电合伙人Josh Wilson了解集体诉讼详情 [11]

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=144422&from=3  CLASS PER ...

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.co ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https:// ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA) and certain officers.  The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and Novemb ...

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https:// ...